Diabetes Drug Actos Linked to High Risk of Bladder Cancer

Recent research has linked the diabetes drug Actos to a risk of bladder cancer. Users may face an increased risk the longer the medication is used. In August 2011, dihydrocodeine 30mg the FDA approved new warning label information about the potential risk of bladder cancer from Actos, ActoPlus Met and Duetact, which all contain the active ingredient pioglitazone. Users are now advised to contact their doctor if the experience possible signs of bladder cancer while using Actos. Possible symptoms include red color in the urine, new or worsening urinary urgency or pain during urination.

Actos was introduced by Takeda Pharmaceuticals in 1999. As a result of aggressive marketing, the drug manufacturer generated over $3billion in Actos sales in 2010 alone.

he FDA has issued a new warning of increased bladder cancer risk associated with use of the diabetes drug Actos (pioglitazone).

The warning comes after a review of data from a five-year analysis of an ongoing study of Actos by the manufacturer, Takeda Pharmaceuticals.

The results show that although there was no increased risk of bladder cancer among Actos users overall, there was an increased risk of bladder cancer among those who had used the drug the longest. There was also a greater risk of bladder cancer among Actos users who had been exposed to the highest cumulative dose of the drug.

Officials say information about this risk will be added to the label of the drug as well as the patient medication guide.

FDA officials say in light of this new information, Actos should not be prescribed to people with bladder cancer or people with a history of bladder cancer.

In September, the FDA launched a safety review of Actos after initial data from the manufacturer’s ongoing 10-year study suggested that the drug may increase the risk of bladder cancer.

The agency says it is also aware of a recent epidemiological study in France that also suggests an increased risk of bladder cancer associated with Actos. Based on this study, France has suspended use of the drug and advised not starting Actos in new patients.

Actos is part of a class of drugs known as thiazolidinediones that is used to treat type 2 diabetes. It is designed to help control blood sugar levels by increasing the body’s sensitivity to insulin.

If you or a loved one has type 2 diabetes and has taken Actos for over a year and developed bladder cancer, contact the injury lawyers at the Manchin Injury Law Group to obtain a free case evaluation at 304-367-1862.

Legal claims are being pursued for users of Actos, ActoPlus Met, and Duetact who have been diagnosed with bladder cancer as a result of Takeda Pharmaceutical’s failure to adequately research the medication or warn about the side effects.